N. Eastley, T. McCulloch, C. Esler, I. Hennig i inni. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. „Eur J Surg Oncol”. 42 (7), s. 1071–1083, 2016. DOI: 10.1016/j.ejso.2016.02.012. PMID: 26965303.
B. Kasper. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations. „Oncol Res Treat”. 38 (5), s. 244–248, 2015. DOI: 10.1159/000381909. PMID: 25896775.
M. Ghert, X. Yao, T. Corbett, A.A. Gupta i inni. Treatment and follow-up strategies in desmoid tumours: a practice guideline. „Curr Oncol”. 21 (4), 2014. DOI: 10.3747/co.21.2112. PMID: 25089635.
D.L. van Broekhoven, D.J. Grünhagen, M.A. den Bakker, T. van Dalen i inni. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. „Ann Surg Oncol”. 22 (9), s. 2817–2823, 2015. DOI: 10.1245/s10434-015-4632-y. PMID: 26045393.
S. Bonvalot, N. Ternès, M. Fiore, G. Bitsakou i inni. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. „Ann Surg Oncol”. 20 (13), s. 4096–4102, 2013. DOI: 10.1245/s10434-013-3197-x. PMID: 24052312.
M. Al-Jazrawe, M. Au, B. Alman. Optimal therapy for desmoid tumors: current options and challenges for the future. „Expert Rev Anticancer Ther”. 15 (12), s. 1443–1458, 2015. DOI: 10.1586/14737140.2015.1096203. PMID: 26472625.
S. Devata, R. Chugh. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. „Hematol Oncol Clin North Am”. 27 (5), s. 989–1005, 2013. DOI: 10.1016/j.hoc.2013.07.008. PMID: 24093172.
M.V. Enzo, M. Rastrelli, C.R. Rossi, U. Hladnik i inni. The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. „Mol Cell Ther”. 3, s. 1, 2015. DOI: 10.1186/s40591-015-0038-2. PMID: 26056602.
S. Cheon, R. Poon, C. Yu, M. Khoury i inni. Prolonged beta-catenin stabilization and tcf-dependent transcriptional activation in hyperplastic cutaneous wounds. „Lab Invest”. 85 (3), s. 416–425, 2005. DOI: 10.1038/labinvest.3700237. PMID: 15654359.
N.A. Mignemi, D.M. Itani, J.H. Fasig, V.L. Keedy i inni. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. „Cancer Sci”. 103 (12), s. 2173–2180, 2012. DOI: 10.1111/cas.12037. PMID: 23035734.
A.J. Lazar, D. Tuvin, S. Hajibashi, S. Habeeb i inni. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. „Am J Pathol”. 173 (5), s. 1518–1527, 2008. DOI: 10.2353/ajpath.2008.080475. PMID: 18832571.
B. Kasper, P. Ströbel, P. Hohenberger. Desmoid tumors: clinical features and treatment options for advanced disease. „Oncologist”. 16 (5), s. 682–693, 2011. DOI: 10.1634/theoncologist.2010-0281. PMID: 21478276.
G. Guglielmi, A. Cifaratti, G. Scalzo, N. Magarelli. Imaging of superficial and deep fibromatosis. „Radiol Med”. 114 (8), s. 1292–1307, 2009. DOI: 10.1007/s11547-009-0458-7. PMID: 19789958.
E.A. Walker, J.M. Petscavage, P.L. Brian, C.I. Logie i inni. Imaging features of superficial and deep fibromatoses in the adult population. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/215810. PMID: 22966216.
Y. Wang, J. Tang, Y. Luo. Sonographic diagnosis of fibromatosis. „J Clin Ultrasound”. 36 (6). s. 330–334. DOI: 10.1002/jcu.20483. PMID: 18446862.
S. Briand, O. Barbier, D. Biau, A. Bertrand-Vasseur i inni. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. „J Bone Joint Surg Am”. 96 (8), s. 631–638, 2014. DOI: 10.2106/JBJS.M.00988. PMID: 24740659.
C. Colombo, R. Miceli, C. Le Péchoux, E. Palassini i inni. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. „Eur J Cancer”. 51 (2), s. 186–192, 2015. DOI: 10.1016/j.ejca.2014.11.019. PMID: 25500145.
A. Gronchi, P.G. Casali, L. Mariani, S. Lo Vullo i inni. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. „J Clin Oncol”. 21 (7), s. 1390–1397, 2003. DOI: 10.1200/JCO.2003.05.150. PMID: 12663732.
M. Melis, J.S. Zager, V.K. Sondak. Multimodality management of desmoid tumors: how important is a negative surgical margin?. „J Surg Oncol”. 98 (8), s. 594–602, 2008. DOI: 10.1002/jso.21033. PMID: 19072851.
P.D. Peng, O. Hyder, M.N. Mavros, R. Turley i inni. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. „Ann Surg Oncol”. 19 (13), s. 4036–4042, 2012. DOI: 10.1245/s10434-012-2634-6. PMID: 22972507.
K. Huang, H. Fu, Y.Q. Shi, Y. Zhou i inni. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. „J Surg Oncol”. 100 (7), s. 563–569, 2009. DOI: 10.1002/jso.21384. PMID: 19722232.
E. Stoeckle, J.M. Coindre, M. Longy, M.B. Binh i inni. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. „Eur J Surg Oncol”. 35 (2), s. 129–134, 2009. DOI: 10.1016/j.ejso.2008.06.1495. PMID: 18760561.
J.T. Mullen, T.F. Delaney, W.K. Kobayashi, J. Szymonifka i inni. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. „Ann Surg Oncol”. 19 (13), s. 4028–4035, 2012. DOI: 10.1245/s10434-012-2638-2. PMID: 22965569.
I. Gluck, K.A. Griffith, J.S. Biermann, F.Y. Feng i inni. Role of radiotherapy in the management of desmoid tumors. „Int J Radiat Oncol Biol Phys”. 80 (3), s. 787–792, 2011. DOI: 10.1016/j.ijrobp.2010.02.053. PMID: 20615622.
S. Salas, A. Dufresne, B. Bui, J.Y. Blay i inni. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. „J Clin Oncol”. 29 (26), s. 3553–3558, 2011. DOI: 10.1200/JCO.2010.33.5489. PMID: 21844500.
A.M. Crago, B. Denton, S. Salas, A. Dufresne i inni. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. „Ann Surg”. 258 (2), s. 347–353, 2013. DOI: 10.1097/SLA.0b013e31828c8a30. PMID: 23532110.
J.M. Cates, T.P. Stricker. Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. „Am J Surg Pathol”. 38 (12), s. 1707–1714, 2014. DOI: 10.1097/PAS.0000000000000276. PMID: 25392923.
K. Huang, C.M. Wang, J.G. Chen, C.Y. Du i inni. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. „Am J Surg”. 207 (6), s. 847–854, 2014. DOI: 10.1016/j.amjsurg.2013.08.007. PMID: 24119719.
W.G. Zeng, Z.X. Zhou, J.W. Liang, H.R. Hou i inni. Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution. „Tumour Biol”. 35 (8), s. 7513–7521, 2014. DOI: 10.1007/s13277-014-2002-1. PMID: 24789435.
A.T. Deyrup, M. Tretiakova, A.G. Montag. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. „Cancer”. 106 (1), s. 208–213, 2006. DOI: 10.1002/cncr.21553. PMID: 16333857.
A. Hansmann, C. Adolph, T. Vogel, A. Unger i inni. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. „Cancer”. 100 (3), s. 612–620, 2004. DOI: 10.1002/cncr.11937. PMID: 14745880.
S. Signoroni, M. Frattini, T. Negri, E. Pastore i inni. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. „Clin Cancer Res”. 13 (17), s. 5034–5040, 2007. DOI: 10.1158/1078-0432.CCR-07-0336. PMID: 17785554.
S.B. Joglekar, P.S. Rose, F. Sim, S. Okuno i inni. Current perspectives on desmoid tumors: the mayo clinic approach. „Cancers (Basel)”. 3 (3), s. 3143–3155, 2011. DOI: 10.3390/cancers3033143. PMID: 24212949.
S.X. Skapek, W.S. Ferguson, L. Granowetter, M. Devidas i inni. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. „J Clin Oncol”. 25 (5), s. 501–506, 2007. DOI: 10.1200/JCO.2006.08.2966. PMID: 17290057.
R.L. van der Hul, C. Seynaeve, B.N. van Geel, J. Verweij. Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity. „Sarcoma”. 7 (3-4), s. 153–157, 2003. DOI: 10.1080/13577140310001644779. PMID: 18521380.
A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis i inni. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. „Acta Oncol”. 50 (3), s. 455–461, 2011. DOI: 10.3109/0284186X.2010.509105. PMID: 20799916.
D. Garbay, A. Le Cesne, N. Penel, C. Chevreau i inni. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). „Ann Oncol”. 23 (1), s. 182–186, 2012. DOI: 10.1093/annonc/mdr051. PMID: 21444357.
A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis i inni. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. „Eur J Cancer”. 45 (17), s. 2930–2934, 2009. DOI: 10.1016/j.ejca.2009.08.016. PMID: 19767198.
G. Wehl, J. Rossler, J.E. Otten, N. Boehm i inni. Response of progressive fibromatosis to therapy with liposomal doxorubicin. „Onkologie”. 27 (6), s. 552–556, 2004. DOI: 10.1159/000081337. PMID: 15591714.
S.H. Okuno, J.H. Edmonson. Combination chemotherapy for desmoid tumors. „Cancer”. 97 (4), s. 1134–1135, 2003. DOI: 10.1002/cncr.11189. PMID: 12569616.
N. Penel, A. Le Cesne, B.N. Bui, D. Perol i inni. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. „Ann Oncol”. 22 (2), s. 452–457, 2011. DOI: 10.1093/annonc/mdq341. PMID: 20622000.
R. Chugh, J.K. Wathen, S.R. Patel, R.G. Maki i inni. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. „Clin Cancer Res”. 16 (19), s. 4884–4891, 2010. DOI: 10.1158/1078-0432.CCR-10-1177. PMID: 20724445.
M.C. Heinrich, G.A. McArthur, G.D. Demetri, H. Joensuu i inni. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). „J Clin Oncol”. 24 (7), s. 1195–1203, 2006. DOI: 10.1200/JCO.2005.04.0717. PMID: 16505440.
A. Dufresne, L. Alberti, M. Brahmi, S. Kabani i inni. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. „BMC Cancer”. 14, s. 632, 2014. DOI: 10.1186/1471-2407-14-632. PMID: 25174682.
M.M. Gounder, R.A. Lefkowitz, M.L. Keohan, D.R. D’Adamo i inni. Activity of Sorafenib against desmoid tumor/deep fibromatosis. „Clin Cancer Res”. 17 (12), s. 4082–4090, 2011. DOI: 10.1158/1078-0432.CCR-10-3322. PMID: 21447727.
R.B. Keus, R.A. Nout, J.Y. Blay, J.M. de Jong i inni. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). „Ann Oncol”. 24 (10), s. 2672–2676, 2013. DOI: 10.1093/annonc/mdt254. PMID: 23868907.
D.L. van Broekhoven, J.P. Deroose, S. Bonvalot, A. Gronchi i inni. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. „Br J Surg”. 101 (13), s. 1674–1680, 2014. DOI: 10.1002/bjs.9659. PMID: 25296896.
B.A. Valentine, F. Del Piero, R.B. Edwards. Intramuscular desmoid tumor (musculoaponeurotic fibromatosis) in two horses. „Vet Pathol”. 36 (5), s. 468–470, Sep 1999. DOI: 10.1354/vp.36-5-468. PMID: 10490218.
N. Eastley, T. McCulloch, C. Esler, I. Hennig i inni. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. „Eur J Surg Oncol”. 42 (7), s. 1071–1083, 2016. DOI: 10.1016/j.ejso.2016.02.012. PMID: 26965303.
B. Kasper. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations. „Oncol Res Treat”. 38 (5), s. 244–248, 2015. DOI: 10.1159/000381909. PMID: 25896775.
M. Ghert, X. Yao, T. Corbett, A.A. Gupta i inni. Treatment and follow-up strategies in desmoid tumours: a practice guideline. „Curr Oncol”. 21 (4), 2014. DOI: 10.3747/co.21.2112. PMID: 25089635.
J.J. Reitamo, P. Häyry, E. Nykyri, E. Saxén. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. „Am J Clin Pathol”. 77 (6), s. 665–673, 1982. PMID: 7091046.
D.L. van Broekhoven, D.J. Grünhagen, M.A. den Bakker, T. van Dalen i inni. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. „Ann Surg Oncol”. 22 (9), s. 2817–2823, 2015. DOI: 10.1245/s10434-015-4632-y. PMID: 26045393.
J.J. Reitamo, T.M. Scheinin, P. Häyry. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. „Am J Surg”. 151 (2), s. 230–237, 1986. PMID: 3946757.
J.J. Lewis, P.J. Boland, D.H. Leung, J.M. Woodruff i inni. The enigma of desmoid tumors. „Ann Surg”. 229 (6), s. 866–873, 1999. PMID: 10363901.
F.M. Enzinger, M. Shiraki. Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years. „Cancer”. 20 (7), s. 1131–1140, 1967. PMID: 6027003.
A. McDougall, G. McGarrity. Extra-abdominal desmoid tumours. „J Bone Joint Surg Br”. 61-B (3), s. 373–377, 1979. PMID: 479262.
N.H. Jenkins, L.S. Freedman, B. McKibbin. Spontaneous regression of a desmoid tumour. „J Bone Joint Surg Br”. 68 (5), s. 780–781, 1986. PMID: 3782245.
S. Bonvalot, N. Ternès, M. Fiore, G. Bitsakou i inni. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. „Ann Surg Oncol”. 20 (13), s. 4096–4102, 2013. DOI: 10.1245/s10434-013-3197-x. PMID: 24052312.
M. Al-Jazrawe, M. Au, B. Alman. Optimal therapy for desmoid tumors: current options and challenges for the future. „Expert Rev Anticancer Ther”. 15 (12), s. 1443–1458, 2015. DOI: 10.1586/14737140.2015.1096203. PMID: 26472625.
S. Devata, R. Chugh. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. „Hematol Oncol Clin North Am”. 27 (5), s. 989–1005, 2013. DOI: 10.1016/j.hoc.2013.07.008. PMID: 24093172.
M.V. Enzo, M. Rastrelli, C.R. Rossi, U. Hladnik i inni. The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. „Mol Cell Ther”. 3, s. 1, 2015. DOI: 10.1186/s40591-015-0038-2. PMID: 26056602.
S. Cheon, R. Poon, C. Yu, M. Khoury i inni. Prolonged beta-catenin stabilization and tcf-dependent transcriptional activation in hyperplastic cutaneous wounds. „Lab Invest”. 85 (3), s. 416–425, 2005. DOI: 10.1038/labinvest.3700237. PMID: 15654359.
N.A. Mignemi, D.M. Itani, J.H. Fasig, V.L. Keedy i inni. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. „Cancer Sci”. 103 (12), s. 2173–2180, 2012. DOI: 10.1111/cas.12037. PMID: 23035734.
A.J. Lazar, D. Tuvin, S. Hajibashi, S. Habeeb i inni. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. „Am J Pathol”. 173 (5), s. 1518–1527, 2008. DOI: 10.2353/ajpath.2008.080475. PMID: 18832571.
B. Kasper, P. Ströbel, P. Hohenberger. Desmoid tumors: clinical features and treatment options for advanced disease. „Oncologist”. 16 (5), s. 682–693, 2011. DOI: 10.1634/theoncologist.2010-0281. PMID: 21478276.
E.J. Groen, A. Roos, F.L. Muntinghe, R.H. Enting i inni. Extra-intestinal manifestations of familial adenomatous polyposis. „Ann Surg Oncol”. 15 (9), s. 2439–2450, 2008. DOI: 10.1245/s10434-008-9981-3. PMID: 18612695.
E. Half, D. Bercovich, P. Rozen. Familial adenomatous polyposis. „Orphanet J Rare Dis”. 4, s. 22, 2009. DOI: 10.1186/1750-1172-4-22. PMID: 19822006.
P. Häyry, J.J. Reitamo, S. Tötterman, D. Hopfner-Hallikainen i inni. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. „Am J Clin Pathol”. 77 (6), s. 674–680, 1982. PMID: 7091047.
K. Dhingra. Antiestrogens-tamoxifen, SERMs and beyond. „Invest New Drugs”. 17 (3), s. 285–311, 1999. PMID: 10665480.
G.A. Santos, I.W. Cunha, R.M. Rocha, C.A. Mello i inni. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. „Biosci Trends”. 4 (1), s. 25–30, 2010. PMID: 20305341.
A.K. Gurbuz, F.M. Giardiello, G.M. Petersen, A.J. Krush i inni. Desmoid tumours in familial adenomatous polyposis. „Gut”. 35 (3), s. 377–381, Mar 1994. PMID: 8150351.
G. Guglielmi, A. Cifaratti, G. Scalzo, N. Magarelli. Imaging of superficial and deep fibromatosis. „Radiol Med”. 114 (8), s. 1292–1307, 2009. DOI: 10.1007/s11547-009-0458-7. PMID: 19789958.
E.A. Walker, J.M. Petscavage, P.L. Brian, C.I. Logie i inni. Imaging features of superficial and deep fibromatoses in the adult population. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/215810. PMID: 22966216.
Y. Wang, J. Tang, Y. Luo. Sonographic diagnosis of fibromatosis. „J Clin Ultrasound”. 36 (6). s. 330–334. DOI: 10.1002/jcu.20483. PMID: 18446862.
S. Briand, O. Barbier, D. Biau, A. Bertrand-Vasseur i inni. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. „J Bone Joint Surg Am”. 96 (8), s. 631–638, 2014. DOI: 10.2106/JBJS.M.00988. PMID: 24740659.
C. Colombo, R. Miceli, C. Le Péchoux, E. Palassini i inni. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. „Eur J Cancer”. 51 (2), s. 186–192, 2015. DOI: 10.1016/j.ejca.2014.11.019. PMID: 25500145.
A. Gronchi, P.G. Casali, L. Mariani, S. Lo Vullo i inni. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. „J Clin Oncol”. 21 (7), s. 1390–1397, 2003. DOI: 10.1200/JCO.2003.05.150. PMID: 12663732.
M.G. Rock, D.J. Pritchard, H.M. Reiman, E.H. Soule i inni. Extra-abdominal desmoid tumors. „J Bone Joint Surg Am”. 66 (9), s. 1369–1374, 1984. PMID: 6501332.
M. Melis, J.S. Zager, V.K. Sondak. Multimodality management of desmoid tumors: how important is a negative surgical margin?. „J Surg Oncol”. 98 (8), s. 594–602, 2008. DOI: 10.1002/jso.21033. PMID: 19072851.
P.D. Peng, O. Hyder, M.N. Mavros, R. Turley i inni. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. „Ann Surg Oncol”. 19 (13), s. 4036–4042, 2012. DOI: 10.1245/s10434-012-2634-6. PMID: 22972507.
K. Huang, H. Fu, Y.Q. Shi, Y. Zhou i inni. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. „J Surg Oncol”. 100 (7), s. 563–569, 2009. DOI: 10.1002/jso.21384. PMID: 19722232.
E. Stoeckle, J.M. Coindre, M. Longy, M.B. Binh i inni. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. „Eur J Surg Oncol”. 35 (2), s. 129–134, 2009. DOI: 10.1016/j.ejso.2008.06.1495. PMID: 18760561.
J.T. Mullen, T.F. Delaney, W.K. Kobayashi, J. Szymonifka i inni. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. „Ann Surg Oncol”. 19 (13), s. 4028–4035, 2012. DOI: 10.1245/s10434-012-2638-2. PMID: 22965569.
I. Gluck, K.A. Griffith, J.S. Biermann, F.Y. Feng i inni. Role of radiotherapy in the management of desmoid tumors. „Int J Radiat Oncol Biol Phys”. 80 (3), s. 787–792, 2011. DOI: 10.1016/j.ijrobp.2010.02.053. PMID: 20615622.
S. Salas, A. Dufresne, B. Bui, J.Y. Blay i inni. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. „J Clin Oncol”. 29 (26), s. 3553–3558, 2011. DOI: 10.1200/JCO.2010.33.5489. PMID: 21844500.
A.M. Crago, B. Denton, S. Salas, A. Dufresne i inni. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. „Ann Surg”. 258 (2), s. 347–353, 2013. DOI: 10.1097/SLA.0b013e31828c8a30. PMID: 23532110.
J.M. Cates, T.P. Stricker. Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. „Am J Surg Pathol”. 38 (12), s. 1707–1714, 2014. DOI: 10.1097/PAS.0000000000000276. PMID: 25392923.
J.J. Nuyttens, P.F. Rust, C.R. Thomas, A.T. Turrisi. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. „Cancer”. 88 (7), s. 1517–1523, 2000. PMID: 10738207.
M.A. Spear, L.C. Jennings, H.J. Mankin, I.J. Spiro i inni. Individualizing management of aggressive fibromatoses. „Int J Radiat Oncol Biol Phys”. 40 (3), s. 637–645, 1998. PMID: 9486614.
M.T. Ballo, G.K. Zagars, A. Pollack. Radiation therapy in the management of desmoid tumors. „Int J Radiat Oncol Biol Phys”. 42 (5), s. 1007–1014, 1998. PMID: 9869223.
K. Huang, C.M. Wang, J.G. Chen, C.Y. Du i inni. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. „Am J Surg”. 207 (6), s. 847–854, 2014. DOI: 10.1016/j.amjsurg.2013.08.007. PMID: 24119719.
W.G. Zeng, Z.X. Zhou, J.W. Liang, H.R. Hou i inni. Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution. „Tumour Biol”. 35 (8), s. 7513–7521, 2014. DOI: 10.1007/s13277-014-2002-1. PMID: 24789435.
A.T. Deyrup, M. Tretiakova, A.G. Montag. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. „Cancer”. 106 (1), s. 208–213, 2006. DOI: 10.1002/cncr.21553. PMID: 16333857.
J. Janinis, M. Patriki, L. Vini, G. Aravantinos i inni. The pharmacological treatment of aggressive fibromatosis: a systematic review. „Ann Oncol”. 14 (2), s. 181–190, Feb 2003. PMID: 12562642.
A. Hansmann, C. Adolph, T. Vogel, A. Unger i inni. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. „Cancer”. 100 (3), s. 612–620, 2004. DOI: 10.1002/cncr.11937. PMID: 14745880.
S. Signoroni, M. Frattini, T. Negri, E. Pastore i inni. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. „Clin Cancer Res”. 13 (17), s. 5034–5040, 2007. DOI: 10.1158/1078-0432.CCR-07-0336. PMID: 17785554.
W.R. Waddell, R.E. Gerner. Indomethacin and ascorbate inhibit desmoid tumors. „J Surg Oncol”. 15 (1), s. 85–90, 1980. PMID: 7421272.
S.B. Joglekar, P.S. Rose, F. Sim, S. Okuno i inni. Current perspectives on desmoid tumors: the mayo clinic approach. „Cancers (Basel)”. 3 (3), s. 3143–3155, 2011. DOI: 10.3390/cancers3033143. PMID: 24212949.
S.X. Skapek, W.S. Ferguson, L. Granowetter, M. Devidas i inni. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. „J Clin Oncol”. 25 (5), s. 501–506, 2007. DOI: 10.1200/JCO.2006.08.2966. PMID: 17290057.
R.L. van der Hul, C. Seynaeve, B.N. van Geel, J. Verweij. Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity. „Sarcoma”. 7 (3-4), s. 153–157, 2003. DOI: 10.1080/13577140310001644779. PMID: 18521380.
A. Azzarelli, A. Gronchi, R. Bertulli, J.D. Tesoro i inni. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. „Cancer”. 92 (5), s. 1259–1264, 2001. PMID: 11571741.
A.J. Weiss, S. Horowitz, R.D. Lackman, R.D. Lackmen. Therapy of desmoid tumors and fibromatosis using vinorelbine. „Am J Clin Oncol”. 22 (2), s. 193–195, 1999. PMID: 10199460.
A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis i inni. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. „Acta Oncol”. 50 (3), s. 455–461, 2011. DOI: 10.3109/0284186X.2010.509105. PMID: 20799916.
S.R. Patel, H.L. Evans, R.S. Benjamin. Combination chemotherapy in adult desmoid tumors. „Cancer”. 72 (11), s. 3244–3247, 1993. PMID: 8242548.
D. Garbay, A. Le Cesne, N. Penel, C. Chevreau i inni. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). „Ann Oncol”. 23 (1), s. 182–186, 2012. DOI: 10.1093/annonc/mdr051. PMID: 21444357.
A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis i inni. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. „Eur J Cancer”. 45 (17), s. 2930–2934, 2009. DOI: 10.1016/j.ejca.2009.08.016. PMID: 19767198.
G. Wehl, J. Rossler, J.E. Otten, N. Boehm i inni. Response of progressive fibromatosis to therapy with liposomal doxorubicin. „Onkologie”. 27 (6), s. 552–556, 2004. DOI: 10.1159/000081337. PMID: 15591714.
S.H. Okuno, J.H. Edmonson. Combination chemotherapy for desmoid tumors. „Cancer”. 97 (4), s. 1134–1135, 2003. DOI: 10.1002/cncr.11189. PMID: 12569616.
N. Penel, A. Le Cesne, B.N. Bui, D. Perol i inni. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. „Ann Oncol”. 22 (2), s. 452–457, 2011. DOI: 10.1093/annonc/mdq341. PMID: 20622000.
R. Chugh, J.K. Wathen, S.R. Patel, R.G. Maki i inni. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. „Clin Cancer Res”. 16 (19), s. 4884–4891, 2010. DOI: 10.1158/1078-0432.CCR-10-1177. PMID: 20724445.
M.C. Heinrich, G.A. McArthur, G.D. Demetri, H. Joensuu i inni. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). „J Clin Oncol”. 24 (7), s. 1195–1203, 2006. DOI: 10.1200/JCO.2005.04.0717. PMID: 16505440.
A. Dufresne, L. Alberti, M. Brahmi, S. Kabani i inni. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. „BMC Cancer”. 14, s. 632, 2014. DOI: 10.1186/1471-2407-14-632. PMID: 25174682.
M.M. Gounder, R.A. Lefkowitz, M.L. Keohan, D.R. D’Adamo i inni. Activity of Sorafenib against desmoid tumor/deep fibromatosis. „Clin Cancer Res”. 17 (12), s. 4082–4090, 2011. DOI: 10.1158/1078-0432.CCR-10-3322. PMID: 21447727.
R.B. Keus, R.A. Nout, J.Y. Blay, J.M. de Jong i inni. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). „Ann Oncol”. 24 (10), s. 2672–2676, 2013. DOI: 10.1093/annonc/mdt254. PMID: 23868907.
D.L. van Broekhoven, J.P. Deroose, S. Bonvalot, A. Gronchi i inni. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. „Br J Surg”. 101 (13), s. 1674–1680, 2014. DOI: 10.1002/bjs.9659. PMID: 25296896.
B.A. Valentine, F. Del Piero, R.B. Edwards. Intramuscular desmoid tumor (musculoaponeurotic fibromatosis) in two horses. „Vet Pathol”. 36 (5), s. 468–470, Sep 1999. DOI: 10.1354/vp.36-5-468. PMID: 10490218.
